A phase I trial and pharmacokinetic study of aflibercept (VEGF trap) in children with refractory solid tumors: A Children's Oncology Group phase I consortium report

Clinical Cancer Research

Volumn 18, Issue 18, 2012, Pages 5081-5089

  Bender, Julia Glade ^a   Blaney, Susan M ^b   Borinstein, Scott ^c   Reid, Joel M ^d   Baruchel, Sylvain ^e   Ahern, Charlotte ^b   Ingle, Ashish M ^f   Yamashiro, Darrell J ^a   Chen, Alice ^g   Weigel, Brenda ^h   Adamson, Peter C ⁱ   Park, Julie R ^j  

^a NewYork Presbyterian Hospital   (United States)

^b TEXAS CHILDREN S CANCER CENTER   (United States)

^c MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

^d MAYO CLINIC   (United States)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f CHILDREN S ONCOLOGY GROUP   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

^h UNIVERSITY OF MINNESOTA   (United States)

ⁱ CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^j UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CEDIRANIB; PLACENTAL GROWTH FACTOR; SORAFENIB; SUNITINIB;

ADOLESCENT; ADRENAL CORTEX CARCINOMA; ADULT; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER PAIN; CANCER RADIOTHERAPY; CANCER RESISTANCE; CHILD; CLEAR CELL SARCOMA; CLINICAL ARTICLE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DYSPHONIA; EPENDYMOMA; EPITHELIOID SARCOMA; EWING SARCOMA; FATIGUE; FEMALE; HEPATOBLASTOMA; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; IMMUNOGENICITY; LARGE CELL CARCINOMA; LEIOMYOSARCOMA; LEUKOPENIA; LIVER CELL CARCINOMA; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NEPHROBLASTOMA; NEUROBLASTOMA; NEUTROPENIA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PILOCYTIC ASTROCYTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEINURIA; RHABDOMYOSARCOMA; SCHOOL CHILD; SIDE EFFECT; SMALL CELL CARCINOMA; SOLID TUMOR; SYNOVIAL SARCOMA; TISSUE NECROSIS; TUMOR BLEEDING; VOICE;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INFANT; MALE; NEOPLASMS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84866371169     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0078     Document Type: Article

References (25)

1. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74.
2. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298-307.
3. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002;99:11393-8.
4. Huang J, Frischer JS, Serur A, Kadenhe A, Yokoi A, McCrudden KW, et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci U S A 2003;100:7785-90.
5. Kadenhe-Chiweshe A, Papa J, McCrudden KW, Frischer J, Bae JO, Huang J, et al. Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation. Mol Cancer Res 2008;6:1-9.
6. Kim ES, Serur A, Huang J, Manley CA, McCrudden KW, Frischer JS, et al. Potent VEGF blockade causes regression of coopted vessels in amodel of neuroblastoma. Proc Natl Acad Sci U S A 2002;99:11399-404.
7. Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P, Sternas L, et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 2010;28:207-14.
8. Cutsem E, Tabernero J, Lakomy R, Prausova J, Ruff P, Van Hazel G, et al. Intravenous (iv) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for secondline treatment of metastatic colorectal cancer (mcrc): results of a multinational phase III trial (efc10262-VELOUR). Ann Oncol 2011;22 Suppl 5:v18.
9. Coleman RL, Duska LR, Ramirez PT, Heymach JV, Kamat AA, Modesitt SC, et al. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol 2011;12:1109-17.
10. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004;114:555-76.
11. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). [cited 2006 Aug 9]. Available from: http://ctep.cancer.gov/protocoldevelopment/electronic- applications/docs/ctcaev3.pdf 2006.
12. Fox E, Aplenc R, Bagatell R, Chuk MK, Dombi E, Goodspeed W, et al. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol 2010;28:5174-81.
13. Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2008;26:399-405.
14. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F, et al. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001;97:3658-61.
15. de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, et al. Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin Cancer Res 2011;17:4872-81.
16. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95.
17. Gordon MS, Margolin K, Talpaz M, Sledge GW, Holmgren E, Benjamin R, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-50.
18. Sonpavde G, Bellmunt J, Schutz F, Choueiri TK. The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients. Curr Oncol Rep 2012;14:295-308.
19. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007;96:1788-95.
20. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-91.
21. Rudge JS, Holash J, Hylton D, Russell M, Jiang S, Leidich R, et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A 2007;104:18363-70.
22. Okur FV, Karadeniz C, Buyukpamukcu M, Oguz A, Yucel A, Cinaz P, et al. Clinical significance of serum vascular endothelial growth factor, endostatin, and leptin levels in children with lymphoma. Pediatr Blood Cancer 2010;55:1272-7.
23. Pavlakovic H, Von Schütz V, Rössler J, Koscielniak E, Havers W, Schweigerer L, et al. Quantification of angiogenesis stimulators in children with solid malignancies. Int J Cancer 2001;92:756-60.
24. Zurita AJ, Jonasch E, Wang X, Khajavi M, Yan S, Du DZ, et al. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2012;23:46-52.
25. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009;6:327-38.